enGene Holdings Balance Sheet

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Year	2023	2022	2021
Cash & Equivalents	81.6	20.43	11.1
Short-Term Investments	0	0.07	0
Cash & Cash Equivalents	81.6	20.51	11.1
Cash Growth	297.88%	84.79%	-
Other Current Assets	3.84	2.08	2.42
Total Current Assets	85.44	22.58	13.52
Property, Plant & Equipment	0.59	0.39	0.57
Other Long-Term Assets	0.93	0.94	0.94
Total Long-Term Assets	1.52	1.33	1.51
Total Assets	86.96	23.91	15.03
Accounts Payable	1.16	0.72	1
Current Debt	0.56	1.27	1.11
Other Current Liabilities	3.54	3.12	1.11
Total Current Liabilities	5.26	5.1	3.22
Long-Term Debt	9.22	27.05	2.45
Other Long-Term Liabilities	0	15.25	9.69
Total Long-Term Liabilities	9.22	42.3	12.14
Total Liabilities	14.47	47.41	15.35
Total Debt	9.78	28.32	3.55
Debt Growth	-65.47%	696.82%	-
Retained Earnings	-199.59	-99.67	-75.21
Comprehensive Income	-1.02	-1.02	-2.18
Shareholders' Equity	72.49	-76.61	-53.44
Net Cash / Debt	71.82	-7.81	7.54
Net Cash Per Share	103.69	-11.92	2.12
Working Capital	80.18	17.48	10.3
Book Value Per Share	104.66	-116.94	-15.00

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).